Calcigard Retard, 20 mg 100 pcs

Angina pectoris, arterial hypertension

Indications

Angina pectoris, arterial hypertension

Pharmacological effect

Calcigard retard has a hypotensive and antianginal effect.

Active ingredient

Nifedipine

Composition

Active ingredient:

nifedipine 20 mg,

Excipients:

lactose;

starch;

MCC;

Twin-80;

polyethylene glycol;

stearic acid;

PVP;

magnesium stearate

sodium lauryl sulfate.

Contraindications

decrease in blood pressure below 90 mm Hg.
severe heart failure
hypersensitivity to the drug Calcigard retard.

Side Effects

From the cardiovascular system: possible – facial hyperemia, feeling of heat, tachycardia, peripheral edema, arterial hypotension. Special instructions – in some patients, especially at the beginning of treatment, angina attacks may occur, which requires discontinuation of the drug.

From the central nervous system: headache, dizziness, increased fatigue, drowsiness. When using high doses of the drug, isolated cases of paresthesia of the extremities, tremor, mild visual disturbances, and sleep disturbances were noted.

From the gastrointestinal tract and liver: nausea, constipation, diarrhea. With long-term use of the drug, there may be cases of increased activity of “liver” transaminases in the blood serum and the occurrence of intrahepatic cholestasis.

From the hematopoietic system: in rare cases – reversible thrombocytopenia, leukopenia, anemia.

From the urinary system: increased daily diuresis; in patients with renal failure – deterioration of kidney function.

Allergic reactions: rarely – urticaria, itching.

Others: with long-term use – myalgia, gynecomastia, gingival hyperplasia, hyperglycemia.

Interaction

With simultaneous use of Calcigard Retard and:

beta-blockers, other antihypertensive drugs, tricyclic antidepressants, diuretics, vasodilators – the hypotensive effect of the drug is enhanced;
in combination with nitrates, tachycardia and increased hypotensive effect are observed; diltiazem – the clearance of nifedipine decreases. When using this combination, it is necessary to reduce the dose of Calcigard Retard and carefully monitor patients;
antiarrhythmic drugs (for example, amiodarone and quinidine) – their negative inotropic effect may increase;
digoxin, the clearance of digoxin decreases, the level of digoxin in plasma increases and the risk of developing digoxin intoxication increases. In these cases, it is necessary to reduce the dose of digoxin and check its level in the blood plasma;
theophylline, it is possible to increase the level of theophylline in plasma, which requires dose adjustment;
cimetidine and, to a lesser extent, ranitidine may increase the plasma level of nifedipine and enhance its effect;
vincristine makes it difficult to remove the latter from the body, which increases the risk of increased side effects caused by vincristine;
cephalosporins, the bioavailability of cephalosporins increases.

Overdose

Symptoms: severe arterial hypotension, cardiac arrhythmia (bradycardia or tachycardia). With increasing intoxication symptoms, hypoxia, cardiogenic shock, and disturbances of consciousness may occur.

Treatment: gastric lavage, intake of activated carbon, intravenous administration of calcium salts. Treatment is symptomatic. Hemodialysis is not effective.

Storage conditions

In a place protected from light and moisture, at a temperature not exceeding 30 °C

Shelf life

3 years

Manufacturer

Torrent Pharmaceuticals Ltd, India